Table 3.
Ongoing clinical studies of BV in the treatment of B cell lymphomas.
| NCT number | Stage | Intervention plan | Disease type | Primary endpoints |
|---|---|---|---|---|
| NCT04745949 | II | BV+R-CHP+Nivolumab | Untreated PMBCL | CRR |
| NCT04587687 | II | BV+Bendamustine | R/R FL | CRR, BOR |
| NCT04404283 | III | BV, Placebo+R2 | R/R DLBCL | PFS |
| NCT03356054 | I/II | BV-R-DHAP | R/R DLBCL | Phase I:MTD;Phase II:CRR |
FL, Follicular lymphoma; PMBCL, Primary mediastinal large B cell lymphoma; R-CHP, Rituximab plus Cyclophosphamide, Adriamycin, Prednisone; R2, Lenalidomide, Rituximab; R-DHAP, Rituximab plus Dexamethasone, Cisplatin, Cytarabine.